SCHEMBL10458908

SCHEMBL10458908

CC(=O)Nc1cc(OC(C)C)c(Cl)cc1Cl

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RORC P51449 4/20 0.61
GAA P10253 2/20 0.56
MAPK1 P28482 1/20 0.56
BRPF1 P55201 1/20 0.51
MEN1 O00255 4/20 0.48
KMT2A Q03164 4/20 0.48
LMNA P02545 3/20 0.48
MAPT P10636 3/20 0.48
NPSR1 Q6W5P4 2/20 0.48
ALDH1A1 P00352 2/20 0.45
HPGD P15428 2/20 0.44
CYP2C9 P11712 2/20 0.44
CYP2C19 P33261 2/20 0.44
KDM4E B2RXH2 1/20 0.44
HTT P42858 1/20 0.43
POLB P06746 1/20 0.42
AGER Q15109 1/20 0.41
PGK1 P00558 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9836947 0.87 GAA (0.56) RORCGAAMAPK1BRPF1MEN1
SCHEMBL28545734 0.86 GAA (0.55) RORCGAAMAPK1MEN1KMT2A
SCHEMBL9730411 0.81 LMNA (0.61) MEN1KMT2ALMNAMAPTNPSR1
SCHEMBL25658878 0.79 ALDH1A1 (0.46) RORCMEN1KMT2ALMNAMAPT
SCHEMBL25179009 0.79 GAA (0.58) RORCGAAMAPK1BRPF1MEN1
SCHEMBL25178180 0.79 GAA (0.49) RORCGAAMAPK1MEN1KMT2A
SCHEMBL25658459 0.78 GAA (0.51) RORCGAAMAPK1MEN1KMT2A
SCHEMBL25658466 0.78 GAA (0.57) RORCGAAMAPK1MEN1KMT2A
SCHEMBL25658456 0.78 GAA (0.57) RORCGAAMAPK1MEN1KMT2A
SCHEMBL25658453 0.78 GAA (0.48) RORCGAAMAPK1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230150931-A1 FABP4/5 INHIBITORS, METHODS OF USE AND METHODS OF MAKING NOVIUS THERAPEUTICS, LLC (US) 2023-05-18 US disclosed
US-4906286-A Herbicidal 2-aryl-1,2,4-triazine-3,5(2H,4H)-diones and sulfur analogs thereof FMC CORPORATION (US) 1990-03-06 US disclosed
EP-0185731-A4 HERBICIDAL 2-ARYL-1,2,4-TRIAZINE-3,5(2H,4H)-DIONES AND SULFUR ANALOGS THEREOF. FMC CORP (US) 1988-11-02 EP disclosed
US-4766233-A Herbicidal 2-aryl-1,2,4-triazine-3,5(2H,4H)-diones and sulfur analogs thereof FMC CORPORATION (US) 1988-08-23 US disclosed
EP-0185731-A1 HERBICIDAL 2-ARYL-1,2,4-TRIAZINE-3,5(2H,4H)-DIONES AND SULFUR ANALOGS THEREOF FMC Corporation (US) 1986-07-02 EP disclosed
WO-1986000072-A1 HERBICIDAL 2-ARYL-1,2,4-TRIAZINE-3,5(2H,4H)-DIONES AND SULFUR ANALOGS THEREOF FMC CORPORATION (US) 1986-01-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230150931-A1 FABP4/5 INHIBITORS, METHODS OF USE AND METHODS OF MAKING FABP5, FABP1, FABP4 RORC 3051/4885GAA 1149/4885MAPK1 4797/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.